Prior studies show that tumor-derived PD-L1 is not required for the efficacy of anti-PD-L1 treatment because host myeloid cells still express PD-L1 that is essential for the response to anti-PD-L1 (Tang et al., 2018). This evidence concerns the gene CD274 and neoplasm.